EU Veterinary GMP Splits From Human GMP: What Regulations 2025/2091 and 2025/2154 Change on 16 July 2026

Executive Summary

As of 16 July 2026, the European Union has, for the first time, a dedicated and directly binding legal act for the good manufacturing practice (GMP) of veterinary medicines. Two Commission Implementing Regulations, (EU) 2025/2091 for veterinary medicinal products and (EU) 2025/2154 for the active substances used as their starting materials, now apply across all EU Member States. Both were adopted on 17 October 2025 and entered into force on 16 November 2025, with a deferred date of application of 16 July 2026 to give industry time to prepare.

The technical requirements will feel familiar because they are largely carried over from the existing EU GMP Guide. The legal character, however, has changed in a way that matters. Veterinary GMP used to sit inside EudraLex Volume 4, a guideline shared with human medicines. It now sits inside a regulation that is directly applicable, with no national transposition and far less room for interpretation. From 16 July 2026, EudraLex Volume 4 governs human medicines, while veterinary manufacturing answers to the new regulations.

For quality teams, the immediate work is not re-engineering the factory. It is reference remapping. Standard operating procedures (SOPs), quality manuals, supplier qualification files, validation master plans, and technical agreements that still cite EudraLex Volume 4 as the governing standard for veterinary lines are now pointing at the wrong instrument. This article explains what changed, who is affected including Canadian veterinary health product and contract manufacturers exporting into EU supply chains, and the practical steps to close the gap before an inspector finds it first.

Introduction

Regulatory change usually arrives as a new expectation. This one arrives as a new legal home for an old expectation, and that distinction is the whole story.

For decades, anyone manufacturing a veterinary medicine in, or importing one into, the European Union followed the same EU Guidelines for Good Manufacturing Practice that governed human medicines: the familiar EudraLex Volume 4. The principles of GMP for veterinary products carried the weight of European law through a directive, but the operational detail lived in guidance. Guidance is persuasive and inspected against, yet it is not, in the strict legal sense, the binding text itself.

Regulation (EU) 2019/6 on veterinary medicinal products, which has applied since 28 January 2022, changed the trajectory. It replaced the older veterinary code (Directive 2001/82/EC) and instructed the European Commission to set out the detail of veterinary GMP in its own implementing acts. Those acts have now landed. Regulation (EU) 2025/2091 and Regulation (EU) 2025/2154 are the result, and 16 July 2026 is the day they bite.

If your quality system treats human GMP and veterinary GMP as the same book with the same cover, this is the moment that assumption stops being safe. The rest of this guide walks through the change with the accuracy your auditors, your notified partners, and your own leadership will expect.

What changed on 16 July 2026?

Direct answer: On 16 July 2026, two Commission Implementing Regulations became applicable across the EU: (EU) 2025/2091, which lays down GMP for veterinary medicinal products, and (EU) 2025/2154, which lays down GMP for active substances used as starting materials in veterinary medicinal products. Both were adopted on 17 October 2025 under Regulation (EU) 2019/6 and are now directly binding law, replacing reliance on the veterinary application of EudraLex Volume 4.

The change is best understood as a split. Human and veterinary GMP shared a single guideline for a long time. From 16 July 2026 they travel on separate legal tracks. EudraLex Volume 4 continues to serve human medicinal products. Veterinary medicines and their active substances are now governed by dedicated regulations that carry the detailed requirements inside the legal text itself, rather than pointing to a guideline for the operational content.

Why veterinary GMP moved from a guideline to a regulation

Direct answer: It matters because a regulation is directly applicable in every EU Member State without being written into national law, and because a binding regulatory text leaves less interpretive space than a guideline. The obligation did not get lighter. It got harder-edged. An inspector now points to an article of a regulation, not a paragraph of guidance.

The old model: one guideline for two very different patients

Under the previous framework, the substance of GMP for veterinary medicines was set out in the EU GMP Guide, EudraLex Volume 4. That is the same body of guidance human-medicine manufacturers use. It is comprehensive, well understood, and inspected against with rigour. But its legal status was that of guidance sitting beneath a directive. Directives bind Member States as to the result, then rely on each country transposing them into national legislation, which can introduce timing gaps and local variation.

The new model: dedicated, directly applicable law

An implementing regulation is different in kind. It applies in full, in the same words, in every Member State from its date of application, with no transposition step. That removes national variation and timing gaps, and it means the detailed GMP expectations for veterinary medicines are now the operative legal text, not a reference document beneath it.

Two consequences follow for quality leaders. First, the expectations are more uniform across the EU, which is helpful for anyone supplying multiple markets. Second, the compliance posture is less forgiving, because the requirement and the law are now the same sentence. Organizations that already run a mature quality system aligned to EU-GMP will recognize almost everything in the new text. The risk is not the content. The risk is documentation that still points to the old instrument. If you want a refresher on how binding EU-GMP compares with other standards your teams may reference, our explainer on EU-GMP versus GPP compliance standards is a useful companion piece.

What Regulation (EU) 2025/2091 covers

Direct answer: Regulation (EU) 2025/2091 lays down the good manufacturing practice for finished veterinary medicinal products. Adopted under Article 93(2) of Regulation (EU) 2019/6, it organizes the familiar GMP architecture across eight chapters, from the pharmaceutical quality system through to certification and batch release by the qualified person. It applies to holders of a manufacturing authorization for veterinary medicines and, through them, to the wider supply chain.

The eight chapters map closely to the structure any EU-GMP practitioner already knows:

1. General provisions: scope and definitions that anchor the regulation.
2. Pharmaceutical quality system: the quality system, product quality reviews, and management responsibility.
3. Personnel: organization, qualification, training, and hygiene.
4. Premises and equipment: design, qualification, maintenance, and control of manufacturing areas.
5. Documentation: records, specifications, master and batch documentation, and data integrity expectations.
6. Production: manufacturing operations, prevention of cross-contamination, and process controls.
7. Quality control: sampling, testing, stability monitoring, and out-of-specification handling.
8. Certification and batch release: the qualified person's responsibilities for certifying and releasing each batch.

Because the marketing authorization holder (MAH) sits at the top of this chain, the regulation reinforces obligations that quality teams should already recognize: keeping specifications aligned to the terms of the marketing authorization, communicating approved or submitted variations to the manufacturer without delay, evaluating the results of periodic product quality reviews, and holding a written agreement with each manufacturer that defines responsibilities on both sides. Where those written agreements are thin or out of date, they become an easy inspection finding. Our guidance on writing SOPs that pass a Health Canada inspection translates directly to the discipline EU inspectors expect here.

What Regulation (EU) 2025/2154 covers

Direct answer: Regulation (EU) 2025/2154 lays down the good manufacturing practice for active substances used as starting materials in veterinary medicinal products, the veterinary equivalent of API GMP. It applies to active substance manufacturers in the veterinary chain and, critically, to the finished-product manufacturers who must qualify and rely on them. It shares the 16 July 2026 date of application with 2025/2091.

Active substance GMP has always been the quieter half of the manufacturing chain, and the half where supplier oversight most often fails. The new regulation makes the veterinary API expectations explicit and binding in their own right, rather than borrowing them by analogy from the human-medicine API guidance. For a finished-product manufacturer, the immediate implication is supplier qualification. Your active substance suppliers for veterinary lines now sit under a named veterinary regulation, and your qualification files, audit scopes, and technical agreements should reference it accordingly.

This is the same accountability principle regulators everywhere are tightening: you cannot outsource a process and outsource the responsibility with it. We explored that theme from the United States angle in who is accountable when your contract manufacturer fails, and the EU veterinary regime now draws the same line.

Who is affected, including Canadian exporters

Direct answer: Anyone who manufactures, imports, or holds a marketing authorization for a veterinary medicine placed on the EU market is affected, along with the active substance manufacturers who supply them. That reach extends well beyond Europe. Canadian veterinary health product makers and contract manufacturers that supply EU veterinary chains are pulled in through their EU customers' supplier qualification and importation obligations.

EU manufacturers, importers, and MAHs

Holders of a manufacturing or import authorization for veterinary medicines are the direct addressees. Their quality systems, batch certification practices, and documentation must demonstrably meet the new regulations from the date of application. Importers into the EU carry particular exposure, because the batch certification and control expectations attach at the point the product enters the Union.

Canadian veterinary health product and contract manufacturers

Canada regulates veterinary products on a separate track. Domestic veterinary health products follow Health Canada's notification regime, which we cover in detail in our guide to veterinary health product notification in Canada. That Canadian pathway is unchanged by the EU move. The exposure is indirect but real: if you are a Canadian site manufacturing or supplying active substances or finished veterinary medicines into an EU supply chain, your European customers must now qualify you against Regulation (EU) 2025/2091 or 2025/2154, not against the veterinary reading of EudraLex Volume 4. Expect updated audit questionnaires, revised technical agreements, and requests to re-map your quality documentation references. Canadian producers already navigating EU market access for cannabis will recognize the pattern from our EU-GMP and GACP certification roadmap; the veterinary chain now demands the same reference precision.

The reference remapping problem

Direct answer: The single most common gap this change creates is a documentation one. Quality manuals, SOPs, specifications, supplier qualification files, validation master plans, and technical agreements that cite EudraLex Volume 4 as the governing GMP standard for veterinary lines are now citing an instrument that no longer applies to veterinary products. The fix is a controlled reference remapping to Regulation (EU) 2025/2091 and 2025/2154, executed through your change control system, not a quiet find-and-replace.

The trap here is complacency. Because the technical requirements are largely carried over, it is tempting to conclude that nothing needs to change. The European Commission even published Tables of Correspondence to map the old GMP guide content to the new regulatory articles, which reinforces the same-requirements impression. But a quality system is judged on whether it references the correct governing instrument, and an inspector who sees a veterinary SOP citing only EudraLex Volume 4 after 16 July 2026 has a legitimate, and easily written, observation.

Reference remapping should be treated as a documentation change with these disciplines:

• Log it in change control. Every affected document gets a change request, an impact assessment, an approval, and an effective date. This is exactly the audit-trail rigour we described in why your CAPA keeps failing.
• Use the Tables of Correspondence as evidence, not as the change itself. They justify that requirements are preserved. They do not update your documents for you.
• Do not extend the remap to the requirement text unless the regulation actually differs. Over-correcting invents work and can introduce errors. Change the citation and any genuinely altered expectation, and leave stable requirements stable.
• Version and re-approve technical agreements. Agreements with manufacturers, active substance suppliers, and importers should name the correct regulation and reflect current responsibilities.

EU Veterinary GMP Transition Checklist

Use this checklist to structure a defensible transition. It doubles as an inspection-readiness self-assessment.

• Confirm which of your product and active substance lines are veterinary and therefore in scope of 2025/2091 and 2025/2154.
• Inventory every quality document (quality manual, SOPs, specifications, protocols, master files) that references EudraLex Volume 4 for veterinary lines.
• Obtain the official texts of Regulation (EU) 2025/2091 and 2025/2154 from EUR-Lex and the Commission's Tables of Correspondence.
• Run a gap assessment mapping each veterinary requirement to the correct new regulatory article.
• Open change controls for reference remapping, with impact assessment and approval.
• Update the pharmaceutical quality system documentation and product quality review procedures to cite the new instrument.
• Rebuild supplier qualification files for veterinary active substance suppliers against 2025/2154.
• Revise and re-execute technical and quality agreements with manufacturers, suppliers, and importers.
• Update validation master plans and qualification protocols where they reference the governing GMP standard.
• Confirm qualified person procedures for certification and batch release name the correct regulation.
• Brief and train affected staff, and record the training.
• Verify importer batch-certification controls for EU entry points reflect the new requirements.

Common Mistakes

Even well-run quality systems stumble on a change like this. The recurring errors we see are predictable and avoidable.

Assuming nothing changed because the requirements are familiar. The content is carried over, so teams conclude there is no work to do. The legal instrument changed, and documentation that cites the wrong instrument is a finding regardless of how good the underlying practice is.

Treating 2025/2154 as an afterthought. Active substance GMP is the part of the chain most likely to be overlooked, yet supplier qualification against the new veterinary API regulation is where finished-product manufacturers carry real exposure.

Doing an uncontrolled find-and-replace. Swapping references outside change control creates its own data-integrity and traceability problem. The remap must be logged, assessed, and approved.

Forgetting the technical agreements. SOPs get attention; contracts do not. Out-of-date agreements that still reference EudraLex Volume 4 for veterinary responsibilities are a soft target in an inspection.

Over-correcting the requirement text. Some teams rewrite stable requirements to be safe, introducing errors and inconsistency. Change the citation and any genuinely different expectation, and leave the rest alone.

Missing the Canadian export exposure. Canadian sites supplying EU veterinary chains sometimes assume this is a purely European problem. Their EU customers' qualification obligations pull them in directly.

Frequently Asked Questions

When did EU veterinary GMP become binding under the new regulations?

The two Commission Implementing Regulations, (EU) 2025/2091 and (EU) 2025/2154, were adopted on 17 October 2025 and entered into force on 16 November 2025. They apply from 16 July 2026. That application date is the point at which compliance is expected across all EU Member States.

What is the difference between Regulation (EU) 2025/2091 and 2025/2154?

Regulation (EU) 2025/2091 sets the GMP for finished veterinary medicinal products. Regulation (EU) 2025/2154 sets the GMP for active substances used as starting materials in veterinary medicinal products, the veterinary API equivalent. They share the same adoption date and the same 16 July 2026 date of application.

Is EudraLex Volume 4 still valid for veterinary products?

Not as the governing instrument. From 16 July 2026, EudraLex Volume 4 continues to serve human medicinal products, while veterinary manufacturing is governed by the new regulations. Documents that still cite Volume 4 for veterinary lines should be remapped to 2025/2091 and 2025/2154.

Do the requirements actually change, or just the legal basis?

The detailed technical requirements are largely carried over from the existing EU GMP Guide, and the Commission published Tables of Correspondence to demonstrate that continuity. The legal character changed: veterinary GMP is now a directly applicable regulation rather than guidance beneath a directive.

How does this affect Canadian companies?

Canadian veterinary health product rules are unchanged. The exposure is indirect. Canadian manufacturers and active substance suppliers feeding EU veterinary supply chains will be qualified by their EU customers against the new regulations, so they should expect updated audits, technical agreements, and documentation-reference requests.

What is the first thing a quality team should do?

Inventory every veterinary quality document that references EudraLex Volume 4, then run a gap assessment against the new regulatory articles and open controlled changes to remap the references. Start with the pharmaceutical quality system documentation, supplier qualification files, and technical agreements.

How MFLRC Can Help

MF License and Regulatory Consultants helps manufacturers, importers, and marketing authorization holders turn a legal-instrument change into a controlled, defensible transition rather than a scramble before the next inspection. Our senior consultants work across pharmaceuticals, veterinary chains, natural health products, cannabis, medical devices, and food, with deep EU-GMP and Health Canada experience.

For the EU veterinary GMP transition specifically, we support:

• Gap assessments against Regulation (EU) 2025/2091 and 2025/2154, mapping every requirement to the correct new article and grading your current state.
• SOP and quality manual reference remediation, executed through proper change control so your documentation cites the right instrument with a clean audit trail. Explore our quality assurance services for the full scope.
• Supplier qualification file rebuilds for veterinary active substance suppliers, including audit questionnaires and technical agreement updates.
• Validation master plan updates where your validation programme references the governing GMP standard, backed by our pharmaceutical validation services.
• Licensing, import, and export support for veterinary supply chains, through our regulatory affairs, licensing and import/export practice.
• Inspection-readiness and mock audits so your transition holds up under scrutiny, delivered by our audit services team.

Need help with the EU veterinary GMP transition? Book a consultation with MFLRC for expert guidance tailored to your products, sites, and supply chain.

Conclusion

The move to Regulation (EU) 2025/2091 and 2025/2154 is deceptively quiet. The requirements you already meet under EU-GMP are largely the requirements you will meet tomorrow. What changed on 16 July 2026 is the instrument and its legal force: veterinary GMP now lives in directly applicable regulations, and EudraLex Volume 4 has stepped back to human medicines.

That quietness is precisely why it is dangerous. The risk is not that your factory falls short. The risk is that your paperwork still points to a book that no longer governs your veterinary lines, and that an inspector notices before you do. Treat this as a documentation and supplier-qualification programme, run it through change control, and remember the Canadian export angle if you feed EU chains. Handled with discipline, this is a reference-remapping exercise. Handled with complacency, it is a finding waiting to be written.

Sources and References

• EUR-Lex: Commission Implementing Regulation (EU) 2025/2091 of 17 October 2025 laying down good manufacturing practice for veterinary medicinal products. eur-lex.europa.eu
• EUR-Lex: Commission Implementing Regulation (EU) 2025/2154 of 17 October 2025 laying down good manufacturing practice for active substances used as starting materials in veterinary medicinal products. eur-lex.europa.eu
• European Commission (Food Safety): Implementing the EU Regulation on veterinary medicines. food.ec.europa.eu
• European Commission (Public Health): EudraLex Volume 4, EU GMP guidelines. health.ec.europa.eu